Standard insulin therapy lacks autonomous regulation based on real-time blood sugar levels. Eliminating the risk of hypoglycemia and hyperglycemia through self-regulating delivery improves patient safety and metabolic stability.

Full agonism of insulin receptors often leads to hypoglycemia and metabolic instability. Partial agonism provides a controlled glycemic response to prevent dangerous blood glucose drops.

Endogenous peptide hormones suffer from short half-lives due to proteolytic instability and rapid clearance. Enhancing structural rigidity prevents enzymatic breakdown to maintain therapeutic efficacy.